Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology

Summary

This study, through a clinical controlled trial, compared the one-year, three-year, and five-year overall survival rates between patients receiving a treatment plan guided by organoid drug sensitivity and those receiving conventional empirical treatment. Univariate Kaplan-Meier survival analysis was used to compare the differences in overall survival between the two groups. The study aimed to evaluate the application value of tumor organoid drug sensitivity testing in guiding neoadjuvant chemotherapy for bladder cancer.

Conditions

• Bladder Cancer

Interventions

OTHER

Organoid culture

Organoid culture of tumor tissue obtained during patient surgery

Sponsors & Collaborators

• The Second Hospital of Shandong University

  collaborator OTHER

• Qianfoshan Hospital

  collaborator OTHER

• Shandong Provincial Hospital

  collaborator OTHER_GOV

• Shandong Province Third hospital

  collaborator OTHER

• Taian City Central Hospital

  collaborator OTHER

• Weifang People's Hospital

  collaborator OTHER

• Binzhou Medical University

  collaborator OTHER

• The Affiliated Hospital of Qingdao University

  collaborator OTHER

• Jining First People's Hospital

  collaborator OTHER

• Liaocheng People's Hospital

  collaborator OTHER

• Linyi People's Hospital

  collaborator OTHER

• Yantai Yuhuangding Hospital

  collaborator OTHER

• Zibo Central Hospital

  collaborator OTHER_GOV

• Dezhou Hospital Qilu Hospital of Shandong University

  collaborator OTHER

• Zaozhuang Municipal Hospital

  collaborator OTHER

• Qilu Hospital of Shandong University (Qingdao)

  collaborator OTHER

• Qilu Hospital of Shandong University

  lead OTHER

Eligibility

Min Age

18 Years

Max Age

80 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-01-01

Primary Completion

2030-12-31

Completion

2030-12-31

Countries

• China

Study Locations